trending Market Intelligence /marketintelligence/en/news-insights/trending/q7-VcLxk2_EV_ObVkRi2RA2 content esgSubNav
In This List

Rhizen drug receives US FDA's orphan drug designation

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Rhizen drug receives US FDA's orphan drug designation

Alembic Pharmaceuticals Ltd. said its associate company Rhizen Pharmaceuticals SA received the U.S. Food and Drug Administration's orphan drug designation for tenalisib.

Tenalisib, also known as RP6530, is a highly selective and orally active dual PI3K delta/gamma inhibitor used for the treatment of peripheral T-cell lymphoma, a type of blood cancer.

The treatment was previously granted the fast track designation by the FDA.